BioCentury
ARTICLE | Product Development

The transition from platform to product: Jean-Paul Kress on reshaping MorphoSys 

CEO Jean-Paul Kress leads German biotech’s pivot away from its mAb legacy

June 13, 2023 11:32 PM UTC

Nearly four years into his role as CEO of MorphoSys, Jean-Paul Kress is in the midst of engineering a transition that nearly all platform companies face: from a technology and partnering model to an integrated commercial organization.

Perennial questions faced by platform companies are how much capital to allocate to continued technology innovation versus financing programs generated by the platform, and knowing when the tech may no longer be differentiated enough from competitors, warranting transition to a product-centered company. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

MorphoSys AG

BCIQ Target Profiles

CD38